Monday - May 5, 2025

LOGIN  |  REGISTER
Viking Therapeutics
Assertio

Definitive Healthcare to Present at the 51st Annual J.P. Morgan Global Technology, Media and Communications Conference

May 15, 2023 | Last Trade: US$2.78 0.07 -2.29

FRAMINGHAM, Mass., May 15, 2023 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (“Definitive Healthcare”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced that its Chief Executive Officer, Robert Musslewhite, and its Chief Financial Officer, Rick Booth, will present at the 51st Annual J.P. Morgan Global Technology, Media and Communications Conference.

The Definitive Healthcare presentation is scheduled for Monday, May 22, 2023, at 10:00 a.m. Eastern Time. A live webcast of the presentation will be available on the Events page of the Definitive Healthcare investor relations website at https://ir.definitivehc.com/. A replay of the webcast will also be available for a limited time.

About Definitive Healthcare

At Definitive Healthcare, our passion is to transform data, analytics and expertise into healthcare commercial intelligence. We help clients uncover the right markets, opportunities and people, so they can shape tomorrow’s healthcare industry. Our SaaS platform creates new paths to commercial success in the healthcare market, so companies can identify where to go next. Learn more at definitivehc.com.

Investor Contact:
Brian Denyeau
ICR for Definitive Healthcare
brian.denyeau@icrinc.com
646-277-1251

Media Contact:
Danielle Johns
djohns@definitivehc.com

Assertio

Stock Quote

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page